Eric Fels, DO
Nephrology · Allentown, PANPI 1821089590
Payments from drug & device makers
What this record shows
Medtronic accounts for 87.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,120 and has fallen 93.0% since, to $78 in 2024.
Across 33 payments — averaging $47.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Bard Peripheral Vascular, Inc.$110
- Mozarc Medical US LLC$27
- Otsuka America Pharmaceutical, Inc.$19
- Fresenius USA Marketing, Inc.$17
- Ardelyx, Inc.$15
- plus $12 from 1 others
Across 35 payments — averaging $1618.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$57K
What the payments were for
- Travel & lodging$84854%
- Food & beverage$71546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 22 | $1,362 |
| Bard Peripheral Vascular, Inc. | 6 | $110 |
| Mozarc Medical US LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| Covidien LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,563 in reported general payments places this provider in the 70th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 28 | $4,535 |
| Losartan Potassium | 55 | $852 |
| Allopurinol | 57 | $755 |
| Amlodipine Besylate | 58 | $626 |
| Lisinopril | 46 | $606 |
| Spironolactone | 43 | $399 |
| Chlorthalidone | 11 | $330 |
| Metoprolol Succinate | 21 | $279 |
| Hydrochlorothiazide | 25 | $237 |
| Calcitriol | 15 | $230 |
| Furosemide | 21 | $164 |
| Atorvastatin Calcium | 14 | $112 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Allentown
- Nelson KopytAllentown$949K
- Shawn HazlettAllentown$39K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.